HECATEDefine the need.
Identify the patients, where current treatment falls short, and what a new therapy must achieve to make a meaningful difference.
The agentic biotech
Lighting the path to the right molecule.
AI agents choose the patient, define the product and price every experiment before money is spent.
- Bispecifics
- ADCs
- T-cell engagers
15 yearsinside the drug pipeline
4clinical-stage biologics, named inventor
<10 minfrom question to sealed report
The question that comes first
Which molecule
is worth making?
The choice of what to make deserves the same rigor as the science of making it.
Hecate Bio starts with the patients, the clinical evidence and the unmet need. We combine experience in biologics development with AI agents to evaluate opportunities before committing to a target or molecular format.
Our goal: choose a differentiated therapeutic opportunity, understand the risks, and direct experiments toward the questions that matter.
Our approach
Patients first.
Evidence at every step.
Each decision builds on the one before it—and can challenge it when the evidence points elsewhere.
Evaluate the opportunity.
Read the clinical landscape, biology and competitive field together. Assess individual targets and combinations, with the evidence behind each judgment.
Let the profile guide
the molecule.
Define the therapeutic requirements first. Use them to guide the molecular format and the experiments needed to resolve uncertainty.
The Scientific Mind Engine
A foundation for
better decisions.
The Scientific Mind Engine is Hecate’s internal system for evaluating therapeutic opportunities. AI agents organize evidence and challenge assumptions; human scientific judgment sets direction.
Evidence you can trace
Facts are linked to their sources. Judgment is identified as judgment. Unknowns stay visible.
Opportunity at the edge of the known
Clinical results help us locate promising biology nearby—and distinguish it from crowded or untested ground.
Development with a purpose
We are building toward molecular specifications and experimental plans that connect each experiment to a decision.
Today, the engine supports target evaluation and target product profiles. Molecular specification and experimental planning are the next layers in development.
Founder
Built from experience
inside the pipeline.
Drew Waight, PhD
Founder, Hecate Bio
4clinical-stage biologics as named inventor
13patent families, 24 granted patents
24papers, 1,500+ citations
Drew Waight has spent 15 years inside the drug pipeline, not beside it. He is a named inventor on four clinical-stage biologics, including fetrastobart vedotin, a PD-L1 ADC in Phase 3 at Pfizer, and MK-8294, a Merck/Janux conditional T-cell engager where he is first inventor. He holds 13 patent families (24 granted patents).
At Seagen he was the lead computational and structural scientist on the design of novel payloads, solving 14 co-crystal structures, and engineered ADCs against LIV-1, TROP2, PD-L1 and CD228. At Systimmune he built the protein engineering group from scratch (7 PhDs) and co-invented new multispecific T-cell engager formats (4 patent families). At Merck he co-led 4 programs and was protein engineering lead on 4 more. He also co-led the AI/ML initiative that produced BioPhi and developability models used in 15+ programs.
A structural biologist by training (NYU PhD, UCSF postdoc), he has 24 papers and 1,500+ citations.
SeagenSystimmuneMerck
Get in touch
Let’s talk about
what comes next.
For scientific collaborations, partnerships and investor conversations.